The Serendipitous Story of SGLT2 Inhibitors in Heart Failure: New Insights From DECLARE-TIMI 58

Circulation

Volumn 139, Issue 22, 2019, Pages 2537-2541

  Verma, Subodh ^a   Mcmurray, John J V ^b  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

diabetes mellitus; Editorials; heart failure; SGLT2 inhibitors

Indexed keywords

CANAGLIFLOZIN; DAPAGLIFLOZIN; EMPAGLIFLOZIN; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; 2-(3-(4-ETHOXYBENZYL)-4-CHLOROPHENYL)-6-HYDROXYMETHYLTETRAHYDRO-2H-PYRAN-3,4,5-TRIOL; BENZHYDRYL DERIVATIVE; GLUCOSIDE;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR MAGNETIC RESONANCE; DIABETES MELLITUS; DIABETIC PATIENT; DISEASE ASSOCIATION; ESTIMATED GLOMERULAR FILTRATION RATE; HEART EJECTION FRACTION; HEART FAILURE; HEART LEFT VENTRICLE MASS; HOSPITALIZATION; HUMAN; ISCHEMIC HEART DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; THROMBOSIS;

BENZHYDRYL COMPOUNDS; DIABETES MELLITUS, TYPE 2; GLUCOSIDES; HEART FAILURE; HUMANS; SODIUM-GLUCOSE TRANSPORTER 2 INHIBITORS;

EID: 85067270152     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.119.040514     Document Type: Review

References (16)

1. McMurray JJ, Gerstein HC, Holman RR, Pfeffer MA. Heart failure: A cardiovascular outcome in diabetes that can no longer be ignored. Lancet Diabetes Endocrinol. 2014;2: 843-851. doi: 10.1016/S2213-8587(14)70031-2
2. Seferovic PM, Petrie MC, Filippatos GS, Anker SD, Rosano G, Bauersachs J, Paulus WJ, Komajda M, Cosentino F, de Boer RA, Farmakis D, Doehner W, Lambrinou E, Lopatin Y, Piepoli MF, Theodorakis MJ, Wiggers H, Lekakis J, Mebazaa A, Mamas MA, Tschöpe C, Hoes AW, Seferovic JP, Logue J, McDonagh T, Riley JP, Milinkovic I, Polovina M, van Veldhuisen DJ, Lainscak M, Maggioni AP, Ruschitzka F, McMurray JJV. Type 2 diabetes mellitus and heart failure: A position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2018;20: 853-872. doi: 10.1002/ejhf.1170
3. Rørth R, Jhund PS, Mogensen UM, Kristensen SL, Petrie MC, Køber L, McMurray JJV. Risk of incident heart failure in patients with diabetes and asymptomatic left ventricular systolic dysfunction. Diabetes Care. 2018;41: 1285-1291. doi: 10.2337/dc17-2583
4. Verma S, Wanner C, Zewiener I, Ofstad AP, George JT, Fitchett D, Zinman B; EMPA-REG OUTCOME Investigators. Influence of microvascular disease on cardiovascular events in type 2 diabetes [published online March 15, 2019]. J Am Coll Cardiol. doi: 10.1016/j.jacc.2019.03.002. https://www.sciencedirect.com/science/article/pii/S0735109719338070?via%3Dihub
5. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE; for the EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373: 2117-2128. doi: 10.1056/NEJMoa1504720
6. Neal B, Perkovic V, Matthews DR. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377: 2099. doi: 10.1056/NEJMc1712572
7. Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Silverman MG, Zelniker TA, Kuder JF, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Ruff CT, Gause-Nilsson IAM, Fredriksson M, Johansson PA, Langkilde AM, Sabatine MS; for the DECLARE-TIMI 58 Investigators. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380: 347-357. doi: 10.1056/NEJMoa1812389
8. Zelniker TA, Wiviott SD, Raz I, Im K, Goodrich EL, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Furtado RHM, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Sabatine MS. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: A systematic review and meta-analysis of cardiovascular outcome trials. Lancet. 2019;393: 31-39. doi: 10.1016/S0140-6736(18)32590-X
9. Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, Edwards R, Agarwal R, Bakris G, Bull S, Cannon CP, Capuano G, Chu PL, de Zeeuw D, Greene T, Levin A, Pollock C, Wheeler DC, Yavin Y, Zhang H, Zinman B, Meininger G, Brenner BM, Mahaffey KW; CREDENCE Trial Investigators. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy [published online ahead of print April 14, 2019]. N Engl J Med. doi: 10.1056/NEJMoa1811744
10. Furtado RHM, Bonaca MP, Raz I, Zelniker TA, Mosenzon O, Cahn A, Kuder J, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Ruff CT, Nicolau JC, Gause-Nilsson IAM, Fredriksson M, Langkilde AM, Sabatine MS, Wiviott SD. Dapagliflozin and cardiovascular outcomes in patients with type 2 diabetes mellitus and previous myocardial infarction: Subanalysis from the DECLARE-TIMI 58 Trial. Circulation. 2019;139: 2516-2527. doi: 10.1161/CIRCULATIONAHA.119.039996
11. Kato ET, Silverman MG, Mosenzon O, Zelniker TA, Cahn A, Furtado RHM, Kuder J, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Bonaca MP, Ruff CT, Desai AS, Goto S, Johansson PA, Gause-Nilsson I, Johanson P, Langkilde AM, Raz I, Sabatine MS, Wiviott SD. Effect of dapagliflozin on heart failure and mortality in type 2 diabetes mellitus. Circulation. 2019;139: 2528-2536. doi: 10.1161/CIRCULATIONAHA.119.040130
12. Verma S, Poulter NR, Bhatt DL, Bain SC, Buse JB, Leiter LA, Nauck MA, Pratley RE, Zinman B, Ørsted DD, Monk Fries T, Rasmussen S, Marso SP. Effects of liraglutide on cardiovascular outcomes in patients with type 2 diabetes mellitus with or without history of myocardial infarction or stroke. Circulation. 2018;138: 2884-2894. doi: 10.1161/CIRCULATIONAHA.118.034516
13. Verma S, McMurray JJV. SGLT2 inhibitors and mechanisms of cardiovascular benefit: A state-of-The-art review. Diabetologia. 2018;61: 2108-2117. doi: 10.1007/s00125-018-4670-7
14. Verma S, Rawat S, Ho KL, Wagg CS, Zhang L, Teoh H, Dyck JE, Uddin GM, Oudit GY, Mayoux E, Lehrke M, Marx N, Lopaschuk GD. Empagliflozin increases cardiac energy production in diabetes: Novel translational insights into the heart failure benefits of SGLT2 inhibitors. JACC Basic Transl Sci. 2018;3: 575-587. doi: 10.1016/j.jacbts.2018.07.006
15. Verma S, Mazer CD, Yan AT, Mason T, Slabiak A, Bello OO, Opingari E, Fitchett DH, Goldenberg RM, Goodman SG, Farkouh ME, Partridge A, Bonneau C, Bakbak E, Dhingra N, Williams AH, Lambotharan SG, Gupta N, Chowdhury C, Dai DWH, Jüni P, Teoh H, Quan A, Liuni A, Leiter LA, Bhatt DL, Zinman B, Connelly KA; for the EMPA-HEART Investigators. EMPA-HEART CardioLink-6 Trial: A randomized trial evaluating the effect of empagliflozin on left ventricular structure, function and biomarkers in people with type 2 diabetes (T2D) and coronary heart disease. Presented at: 2018 American Heart Association Annual Scientific Sessions; Chicago, IL; November 10-12, 2018. Circulation. 2018;138: E762. Abstract 19332.
16. Verma S, Jüni P, Mazer CD. Pump, pipes, and filter: Do SGLT2 inhibitors cover it all? Lancet. 2019;393: 3-5. doi: 10.1016/S0140-6736(18)32824-1